<DOC>
	<DOCNO>NCT00368121</DOCNO>
	<brief_summary>EMMA-1 open-label , non-randomized , two-stage phase II study . Patients refractory multiple myeloma stage II III relapse disease least one line treatment receive Cetuximab+/-Dexamethasone . The planed treatment duration per patient 16 week . Patients achieve response stable disease 16 week treatment may continue study medication 6 month ( patient receive Cetuximab alone ) 3 month ( patient receive Cetuximab plus Dexamethasone ) . Responding patient relapse follow-up period two year may receive second treatment Cetuximab follow initial study guideline</brief_summary>
	<brief_title>EMMA-1 ( Erbitux Multiple Myeloma )</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Multiple myeloma diagnose accord Duriecriteria stage II III ( Salmon Durie ) Measurable disease Refractory relapse disease least one line treatment Male female &gt; = 18 year age Life expectancy &gt; 12 week ECOG performance status 02 If childbearing potential , willingness use effective contraceptive method study duration 6 month postdosing . No surgery , radiotherapy chemotherapy investigational agent within 30 day study entry Signed write informed consent Asecretory multiple myeloma Patients eligible willing undergo high dose chemotherapy follow autologous stem cell transplantation Prior allogeneic transplantation Prior antibody EGFRpathway target therapy Severe cardiovascular disease like functionally restrict heart rhythm disturbance heart malformation severe hypertension , cardiac insufficiency &gt; NYHAII HIV Infection , Hepatitis B C Brain disorder , psychiatric illness Insufficient bone marrow reserve ( Leucocytes &lt; 1500/µl ; Thrombocytes &lt; 50000/µl ) CreatinineClearance &lt; 30 ml/min Crea &gt; 3.0 mg/dl Bilirubin &gt; 2 mg/dl ; ASAT , ALAT &gt; 100 U/l Pregnancy ( absence confirm serum/urine betaHCG ) breastfeed FEV1 &lt; 50 % reference value Active secondary malignancy Legal incapacity limit legal capacity Having participate another clinical trial investigational agent precede 30 day Known allergic/hypersensitivity reaction compound treatment Other previous malignancy within 5 year , exception history previous basal cell carcinoma skin preinvasive carcinoma cervix Medical psychological condition opinion investigator would permit patient complete study sign meaningful informed consent Known drug abuse/alcohol abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Cetuximab</keyword>
</DOC>